D. ROSS CAMIDGE, M.D., Ph.D.

Following a PhD in Molecular Biology at the Medical Research Council’s Laboratory of Molecular Biology at Cambridge University, UK, Dr Camidge completed his medical training at Oxford University, UK. He then became the first person to double train in Medical Oncology and Clinical Pharmacology in the UK, before joining the University of Colorado, USA from October 2005.

Dr Camidge’s main clinical and research interests are thoracic malignancies and developmental therapeutics. The discoveries he and his team have made have changed the standard of care for the treatment of lung cancer multiple times. He has authored over 300 academic publications, including in the Journal of Thoracic Oncology, Lancet Oncology, and New England Journal of Medicine. He has received numerous awards including, in 2012, the Bonnie J. Addario International Lectureship Award for which he was credited as a ‘Luminary in the quest to eradicate lung cancer’. In 2013 he became the first physician to receive the Hank Baskett Sr. Spirit Award, for which he was credited as being ‘one of the leading minds in lung cancer today’. In 2014, he was nationally recognized by The Quality of Life Center at Claremont University in California as an ‘Exemplary mentor in the positive development of junior colleagues in the profession’. In 2016, the Lung Cancer Foundation presented him with the Breath Away From The Cure Award describing him as ‘Simply one of the best in treating lung cancer today’.

Every year since 2017, he has been internationally recognized as a Highly Cited Researcher ranked in the top 1% of all of Clinical Medicine by Clarivate Analytics Web of Science. Every year from 2019 he has ranked at the ‘World Expert’ level by Expertscape for scholars writing about Lung Neoplasms over the past 10 years. He is also the founding National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) – a collaborative network of 16 US and Canadian sites conducting trials in thoracic oncology, Co-chair of the Elsevier ClinPath (formerly VIA) Oncology Lung Cancer Pathways Committee and a past-member of the National Comprehensive Cancer Network Lung Cancer Committee.